AU759391B2 - Pneumococcal and meningococcal vaccines formulated with interleukin-12 - Google Patents
Pneumococcal and meningococcal vaccines formulated with interleukin-12 Download PDFInfo
- Publication number
- AU759391B2 AU759391B2 AU25965/99A AU2596599A AU759391B2 AU 759391 B2 AU759391 B2 AU 759391B2 AU 25965/99 A AU25965/99 A AU 25965/99A AU 2596599 A AU2596599 A AU 2596599A AU 759391 B2 AU759391 B2 AU 759391B2
- Authority
- AU
- Australia
- Prior art keywords
- composition according
- vaccine
- interleukin
- antigen
- pneumococcal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010065805 Interleukin-12 Proteins 0.000 title claims description 372
- 102000013462 Interleukin-12 Human genes 0.000 title claims description 372
- 229940117681 interleukin-12 Drugs 0.000 title claims description 362
- 229960001973 pneumococcal vaccines Drugs 0.000 title description 6
- 229960005037 meningococcal vaccines Drugs 0.000 title description 3
- 229960005486 vaccine Drugs 0.000 claims description 187
- 230000004044 response Effects 0.000 claims description 136
- 239000000203 mixture Substances 0.000 claims description 108
- 108091007433 antigens Proteins 0.000 claims description 93
- 102000036639 antigens Human genes 0.000 claims description 93
- 239000000427 antigen Substances 0.000 claims description 91
- 239000002671 adjuvant Substances 0.000 claims description 67
- 229940037003 alum Drugs 0.000 claims description 42
- 230000002163 immunogen Effects 0.000 claims description 33
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 239000011707 mineral Substances 0.000 claims description 33
- 239000000725 suspension Substances 0.000 claims description 32
- 150000004676 glycans Chemical class 0.000 claims description 27
- 229920001282 polysaccharide Polymers 0.000 claims description 27
- 239000005017 polysaccharide Substances 0.000 claims description 27
- 230000028993 immune response Effects 0.000 claims description 26
- 230000001681 protective effect Effects 0.000 claims description 13
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 10
- 231100000252 nontoxic Toxicity 0.000 claims description 9
- 230000003000 nontoxic effect Effects 0.000 claims description 9
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims description 7
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 7
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 7
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims description 7
- 102100029095 Exportin-1 Human genes 0.000 claims description 7
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims description 7
- 101150094313 XPO1 gene Proteins 0.000 claims description 7
- 108700002148 exportin 1 Proteins 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims description 4
- 229940124733 pneumococcal vaccine Drugs 0.000 claims description 4
- 108010081690 Pertussis Toxin Proteins 0.000 claims 6
- 108010055044 Tetanus Toxin Proteins 0.000 claims 6
- 229940040731 human interleukin-12 Drugs 0.000 claims 6
- 229940118376 tetanus toxin Drugs 0.000 claims 6
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 109
- 229910017119 AlPO Inorganic materials 0.000 description 89
- 230000000694 effects Effects 0.000 description 59
- 102000004127 Cytokines Human genes 0.000 description 35
- 108090000695 Cytokines Proteins 0.000 description 35
- 238000002255 vaccination Methods 0.000 description 28
- 230000001965 increasing effect Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 230000003053 immunization Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 12
- 108010062580 Concanavalin A Proteins 0.000 description 12
- 108010060123 Conjugate Vaccines Proteins 0.000 description 12
- 108010002616 Interleukin-5 Proteins 0.000 description 12
- 108010014251 Muramidase Proteins 0.000 description 12
- 102000016943 Muramidase Human genes 0.000 description 12
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 12
- 229940031670 conjugate vaccine Drugs 0.000 description 12
- 239000004325 lysozyme Substances 0.000 description 12
- 229960000274 lysozyme Drugs 0.000 description 12
- 235000010335 lysozyme Nutrition 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002443 helper t lymphocyte Anatomy 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 101150085064 menC gene Proteins 0.000 description 6
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 230000000240 adjuvant effect Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- -1 ethanol polyols Chemical class 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229940030960 nonavalent vaccine Drugs 0.000 description 4
- 230000000625 opsonophagocytic effect Effects 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940031416 bivalent vaccine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229960003983 diphtheria toxoid Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108010021083 hen egg lysozyme Proteins 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7452898P | 1998-02-12 | 1998-02-12 | |
| US60/074528 | 1998-02-12 | ||
| PCT/US1999/002847 WO1999040936A2 (en) | 1998-02-12 | 1999-02-10 | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2596599A AU2596599A (en) | 1999-08-30 |
| AU759391B2 true AU759391B2 (en) | 2003-04-10 |
Family
ID=22120049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU25965/99A Ceased AU759391B2 (en) | 1998-02-12 | 1999-02-10 | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1053015A2 (https=) |
| JP (3) | JP2002502882A (https=) |
| KR (1) | KR100585408B1 (https=) |
| CN (1) | CN1200730C (https=) |
| AU (1) | AU759391B2 (https=) |
| BR (1) | BR9907884A (https=) |
| CA (1) | CA2320223A1 (https=) |
| IL (2) | IL137809A0 (https=) |
| WO (1) | WO1999040936A2 (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL137809A0 (en) * | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
| MXPA02000842A (es) | 1999-07-22 | 2002-07-30 | Procter & Gamble | Conjugados de proteasa que tienen sitios de corte protegidos estericamente. |
| CN1373802A (zh) | 1999-07-22 | 2002-10-09 | 宝洁公司 | 在特定表位区域具有氨基酸缺失和取代的枯草杆菌蛋白酶变体 |
| US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
| BR0012660A (pt) | 1999-07-22 | 2002-04-09 | Procter & Gamble | Variante de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| EP2172213B1 (en) | 2003-01-30 | 2013-04-03 | Novartis AG | Injectable vaccines against multiple meningococcal serogroups |
| NZ546430A (en) | 2003-10-02 | 2009-04-30 | Novartis Vaccines & Diagnostic | Liquid vaccines for multiple meningococcal serogroups |
| NZ550533A (en) | 2004-04-30 | 2010-02-26 | Novartis Vaccines & Diagnostic | Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| SI1858920T1 (sl) | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| EP3311836A1 (en) * | 2005-04-08 | 2018-04-25 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| WO2006123164A2 (en) * | 2005-05-19 | 2006-11-23 | The Edward Jenner Institute For Vaccine Research | Lps-binding and bactericidal cytokines and interferons |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
| US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
| EP3263128A3 (en) | 2009-04-14 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
| US10988511B2 (en) | 2009-07-07 | 2021-04-27 | Glaxosmithkline Biologicals Sa | Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens |
| AU2010272243A1 (en) | 2009-07-16 | 2012-03-08 | Novartis Ag | Detoxified Escherichia coli immunogens |
| CN102596240B (zh) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | 包括脑膜炎球菌fHBP序列的杂交多肽 |
| US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
| GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
| GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
| CN102724988B (zh) | 2009-09-30 | 2014-09-10 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽的表达 |
| BR112012009014B8 (pt) | 2009-09-30 | 2022-10-04 | Novartis Ag | Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| CA2779816A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| WO2011080595A2 (en) | 2009-12-30 | 2011-07-07 | Novartis Ag | Polysaccharide immunogens conjugated to e. coli carrier proteins |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| US9744228B2 (en) | 2010-04-07 | 2017-08-29 | Norvartis Ag | Method for generating a parvovirus B19 virus-like particle |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| AU2011276328C1 (en) | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| CA2860331A1 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| ES2687129T3 (es) | 2011-07-25 | 2018-10-23 | Glaxosmithkline Biologicals Sa | Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| EP2755994A2 (en) | 2011-09-14 | 2014-07-23 | Novartis AG | Escherichia coli vaccine combination |
| US9358284B2 (en) | 2011-09-14 | 2016-06-07 | Glaxosmithkline Biologicals Sa | Methods for making saccharide-protein glycoconjugates |
| WO2013084071A2 (en) | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| WO2013124473A1 (en) | 2012-02-24 | 2013-08-29 | Novartis Ag | Pilus proteins and compositions |
| US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
| RU2727476C2 (ru) | 2012-04-26 | 2020-07-21 | Новартис Аг | Антигены и антигенные композиции |
| RU2014151567A (ru) | 2012-05-22 | 2016-07-10 | Новартис Аг | Конъюгат менингококка серогруппы х |
| JP6283674B2 (ja) | 2012-09-18 | 2018-02-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 外膜小胞 |
| TR201808684T4 (tr) | 2012-10-02 | 2018-07-23 | Glaxosmithkline Biologicals Sa | Lineer olmayan sakarit konjügatları. |
| RU2015106791A (ru) | 2012-10-03 | 2016-11-20 | Глэксосмитиклайн Байолоджикалз Са | Иммуногенные композиции |
| CN111249455A (zh) | 2012-11-30 | 2020-06-09 | 葛兰素史密丝克莱恩生物有限公司 | 假单胞菌抗原和抗原组合 |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| CN114544913B (zh) * | 2022-02-23 | 2024-04-09 | 沈阳建筑大学 | 一种土壤调查加密采样布点优化方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998014871A1 (en) * | 1996-09-30 | 1998-04-09 | Emc Corporation | A file transfer utility which employs an intermediate data storage system |
| US5866134A (en) * | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| US6303114B1 (en) * | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| JPH10502366A (ja) * | 1994-07-01 | 1998-03-03 | リカン・リミテッド | ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ |
| DK0784486T3 (da) * | 1994-10-05 | 2006-08-14 | Univ Vanderbilt | Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner |
| GB9422990D0 (en) * | 1994-11-15 | 1995-01-04 | Cortecs Ltd | Immunogenic compositions |
| WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
| AU724743B2 (en) * | 1996-05-31 | 2000-09-28 | Genetics Institute, Llc | IL-12 as an adjuvant for Bordetella Pertussis vaccines |
| IL137809A0 (en) * | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
-
1999
- 1999-02-10 IL IL13780999A patent/IL137809A0/xx active IP Right Grant
- 1999-02-10 JP JP2000531187A patent/JP2002502882A/ja active Pending
- 1999-02-10 CN CNB998038792A patent/CN1200730C/zh not_active Expired - Fee Related
- 1999-02-10 AU AU25965/99A patent/AU759391B2/en not_active Ceased
- 1999-02-10 BR BR9907884-8A patent/BR9907884A/pt not_active IP Right Cessation
- 1999-02-10 EP EP99905924A patent/EP1053015A2/en not_active Withdrawn
- 1999-02-10 WO PCT/US1999/002847 patent/WO1999040936A2/en not_active Ceased
- 1999-02-10 KR KR1020007008806A patent/KR100585408B1/ko not_active Expired - Fee Related
- 1999-02-10 CA CA002320223A patent/CA2320223A1/en not_active Abandoned
-
2000
- 2000-08-10 IL IL137809A patent/IL137809A/en not_active IP Right Cessation
-
2009
- 2009-08-24 JP JP2009193167A patent/JP2010006827A/ja active Pending
-
2010
- 2010-06-24 JP JP2010144063A patent/JP2010265279A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866134A (en) * | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| WO1998014871A1 (en) * | 1996-09-30 | 1998-04-09 | Emc Corporation | A file transfer utility which employs an intermediate data storage system |
| US6303114B1 (en) * | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
Also Published As
| Publication number | Publication date |
|---|---|
| IL137809A (en) | 2007-12-03 |
| CA2320223A1 (en) | 1999-08-19 |
| JP2010265279A (ja) | 2010-11-25 |
| JP2002502882A (ja) | 2002-01-29 |
| JP2010006827A (ja) | 2010-01-14 |
| AU2596599A (en) | 1999-08-30 |
| BR9907884A (pt) | 2000-10-24 |
| EP1053015A2 (en) | 2000-11-22 |
| WO1999040936A2 (en) | 1999-08-19 |
| CN1292706A (zh) | 2001-04-25 |
| KR100585408B1 (ko) | 2006-06-01 |
| IL137809A0 (en) | 2001-10-31 |
| WO1999040936A3 (en) | 1999-10-28 |
| KR20010040898A (ko) | 2001-05-15 |
| CN1200730C (zh) | 2005-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU759391B2 (en) | Pneumococcal and meningococcal vaccines formulated with interleukin-12 | |
| US5334379A (en) | Cytokine and hormone carriers for conjugate vaccines | |
| AU648509B2 (en) | Stable vaccine compositions containing interleukins | |
| EP0471177B1 (en) | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines | |
| EP0789587B2 (en) | Combined meningitis vaccine | |
| JP5670003B2 (ja) | 血清型ＢおよびＣ由来のＮｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ抗原、ならびにさらなる抗原を含む組成物 | |
| Lowell et al. | Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice | |
| EP0655929A1 (en) | Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines | |
| US6841160B2 (en) | Meningococcal vaccines formulated with interleukin-12 | |
| EP1223975B1 (en) | MUCOSAL DTPa VACCINES | |
| WO1999040937A2 (en) | Vaccines comprising interleukin-12 and respiratory syncytial viral antigens | |
| MXPA00007879A (en) | Pneumococcal and meningococcal vaccines formulated with interleukin-12 | |
| Giraldo | Role of adjuvants in HIV vaccine design | |
| MXPA00007881A (en) | Vaccines comprising interleukin-12 and respiratory syncytial viral antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: WYETH HOLDINGS CORPORATION Free format text: FORMER NAME WAS: AMERICAN CYANAMID COMPANY |